About this trial
This is a single-arm prospective, feasibility study evaluating the intravenous contrast-enhanced cone beam computed tomography (IV CBCT) for image guidance during radiotherapy. Patients treated with SFRT will receive IV-contrast enhanced CT and fMRI before treatment for simulation purposes. Additionally, patients will receive mpMRI just before and IV-contrast enhanced CBCT during their second and last fraction of RT, in addition to the standard of care CBCT that is acquired for daily image-guided patient positioning. Patients will undergo both IV-contrast enhanced CBCT and treatment on the TrueBeam with HyperSight imaging capability. We hypothesize IV contrast enhanced CBCT is feasible, well-tolerated by patients and improves the visibility of the target.
Eligibility criteria
Qualifiers
Primary biopsy-proven cancer
Planning to undergo spatially fractionated radiation therapy
Able to provide informed consent
Willingness to participate in follow-up
Disqualifiers
Unable to understand/provide consent
History of allergic reaction to iodinated IV contrast dye (allergy to MR contrast is not an exclusion criteria)
Known renal disease
Single kidney
Trial design
Treatments tested in this trial
- Intravenous contrast-enhanced cone beam computed tomography